LESS: Single-arm study to de-escalate adjuvant endocrine therapy duration in post-menopausal women with HR+ HER2- early-stage breast cancer at very low risk of metastasis von Deluche, Elise, Michiels, Stefan, Fric, Daniele, Perrin, Christophe, Bailleux, Caroline, Bachelot, Thomas, Ko Kivok Yun, Pascal, De Rauglaudre, Gaetan, Mouret-Reynier, Marie-Ange, Le Scodan, Romauld, Vaz-Luis, Ines, Lacroix-Triki, Magali, Guyonneau, Clara, Andre, Fabrice

Volltext

DOLAF: An international multicenter phase II trial of durvalumab (MEDI4736) plus olaparib plus fulvestrant in patients with metastatic or locally advanced ER-positive, HER2-negativ... von Guiu Lahaye, Severine, Balmana Gelpi, Judith, Gauthier, Ludovic, Bigot, Frédéric, Goncalves, Anthony, Frenel, Jean-Sebastien, Bachelot, Thomas, Dalenc, Florence, Mailliez, Audrey, Chakiba, Camille, Genet, Dominique, Dohollou, Nathalie, Desmoulins, Isabelle, Canon, Jean-Luc Re, Guyonneau, Clara, Buisson, Adrien, Chevalier, Louise-Marie, Delaloge, Suzette, Follana, Philippe

Volltext